Implications of applied research for prognosis and therapy of breast cancer

Critical Reviews in Oncology/Hematology

Volumn 65, Issue 3, 2008, Pages 223-234

  Barginear, M F ^a   Bradley, T ^a   Shapira, I ^a   Budman, D R ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Breast cancer; Gene expression profiles; Molecular profiling

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HORMONE; PACLITAXEL; TAMOXIFEN;

BREAST CANCER; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; MICROARRAY ANALYSIS; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 38649116344     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.11.004     Document Type: Review

References (135)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Galea M.H., Blamey R.W., Elston C.E., and Ellis I.O. The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22 (1992) 207-219
3. Ravdin P.M., Siminoff L.A., Davis G.J., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19 (2001) 980-991
4. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
5. Goldhirsch A., Coates A.S., Gelber R.D., Glick J.H., Thurlimann B., and Senn H.J. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17 (2006) 1772-1776
6. Pestalozzi B.C., Luporsi-Gely E., Jost L.M., and Bergh J. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol 16 Suppl 1 (2005) i7-i9
7. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784-1792
8. Chia S.K., Speers C.H., Bryce C.J., Hayes M.M., and Olivotto I.A. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22 (2004) 1630-1637
9. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320 (1989) 479-484
10. Fisher B., Jeong J.H., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet 364 (2004) 858-868
11. Fisher B., Dignam J., Wolmark N., et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89 (1997) 1673-1682
12. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
13. Hanrahan E.O., Valero V., Gonzalez-Angulo A.M., and Hortobagyi G.N. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; t1a,bn0m0): a review of the literature. J Clin Oncol 24 (2006) 2113-2122
14. Rosen P.P., Saigo P.E., Braun Jr. D.W., Weathers E., and DePalo A. Predictors of recurrence in stage i (t1n0m0) breast carcinoma. Ann Surg 193 (1981) 15-25
15. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 (2003) 976-983
16. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 (2005) 2302-2313
17. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol b-27. J Clin Oncol 21 (2003) 4165-4174
18. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
19. Bloom H.J., and Richardson W.W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11 (1957) 359-377
20. Neville A.M., Bettelheim R., Gelber R.D., et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The international (ludwig) breast cancer study group. J Clin Oncol 10 (1992) 696-705
21. Delides G.S., Garas G., Georgouli G., et al. Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med 106 (1982) 126-128
22. Harvey J.M., de Klerk N.H., and Sterrett G.F. Histological grading in breast cancer: interobserver agreement, and relation to other prognostic factors including ploidy. Pathology 24 (1992) 63-68
23. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of american pathologists consensus statement 1999. Arch Pathol Lab Med 124 (2000) 966-978
24. Cross S.S., Start R.D., and Smith J.H. Does delay in fixation affect the number of mitotic figures in processed tissue?. J Clin Pathol 43 (1990) 597-599
25. Robbins P., Pinder S., de Klerk N., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26 (1995) 873-879
26. Crump M., Goss P.E., Prince M., and Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 14 (1996) 66-69
27. Paik S., Bryant J., Park C., et al. Erbb-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 (1998) 1361-1370
28. Diab S.G., Hilsenbeck S.G., de Moor C., et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 16 (1998) 1655-1660
29. Fountzilas G., Nicolaides C., Aravantinos G., et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study. Oncology 55 (1998) 508-512
30. Carter C.L., Allen C., and Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63 (1989) 181-187
31. Nemoto T., Vana J., Bedwani R.N., Baker H.W., McGregor F.H., and Murphy G.P. Management and survival of female breast cancer: results of a national survey by the American college of surgeons. Cancer 45 (1980) 2917-2924
32. Macmahon C.E., and Cahill J.L. The evolution of the concept of the use of surgical castration in the palliation of breast cancer in pre-menopausal females. Ann Surg 184 (1976) 713-716
33. Jensen E.V., Block G.E., Smith S., Kyser K., and DeSombre E.R. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 34 (1971) 55-70
34. Wittliff J.L. Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1 (1974) 109-118
35. Wittliff J.L. Steroid-hormone receptors in breast cancer. Cancer 53 (1984) 630-643
36. Horowitz K.B., and McGuire W.L. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189 (1975) 726-727
37. Fisher B. National surgical adjuvant breast and bowel project breast cancer prevention trial: a reflective commentary. J Clin Oncol 17 (1999) 1632-1639
38. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 (1980) 2884-2888
39. Pichon M.F., Broet P., Magdelenat H., et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 73 (1996) 1545-1551
40. Fisher E.R., Dignam J., Tan-Chiu E., et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of protocol b-17: intraductal carcinoma. Cancer 86 (1999) 429-438
41. Fisher B., Redmond C., Fisher E.R., and Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol b-06. J Clin Oncol 6 (1988) 1076-1087
42. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the atac randomised trial. Lancet 359 (2002) 2131-2139
43. Howell A., Cuzick J., Baum M., et al. Results of the atac (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
44. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
45. Pertschuk L.P., Feldman J.G., Kim Y.D., et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with er1d5 predicts breast cancer endocrine response more accurately than h222sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77 (1996) 2514-2519
46. Taylor C.R. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer 77 (1996) 2419-2422
47. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
48. Love R.R., Duc N.B., Allred D.C., et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal vietnamese and chinese women with operable breast cancer. J Clin Oncol 20 (2002) 2559-2566
49. Elledge R.M., Green S., Pugh R., et al. Estrogen receptor (er) and progesterone receptor (pgr), by ligand-binding assay compared with er, pgr and ps2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer 89 (2000) 111-117
50. Allred D.C., Bustamante M.A., Daniel C.O., Gaskill H.V., and Cruz A.B. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125 (1990) 107-113
51. Hohenberger P., Felgner C., Haensch W., and Schlag P.M. Tumor oxygenation correlates with molecular growth determinants in breast cancer. Breast Cancer Res Treat 48 (1998) 97-106
52. Kurebayashi J. Biological and clinical significance of her2 overexpression in breast cancer. Breast Cancer 8 (2001) 45-51
53. Cooper C., Liu G.Y., Niu Y.L., Santos S., Murphy L.C., and Watson P.H. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res 10 (2004) 8720-8727
54. Schechter A.L., Hung M.C., Vaidyanathan L., et al. The neu gene: an erbb-homologous gene distinct from and unlinked to the gene encoding the egf receptor. Science 229 (1985) 976-978
55. Bargmann C.I., Hung M.C., and Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319 (1986) 226-230
56. Beckmann M.W., Niederacher D., Massenkeil G., et al. Expression analyses of epidermal growth factor receptor and her-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 53 (1996) 441-447
57. Taucher S., Rudas M., Mader R.M., et al. Do we need her-2/neu testing for all patients with primary breast carcinoma?. Cancer 98 (2003) 2547-2553
58. Tandon A.K., Clark G.M., Chamness G.C., Ullrich A., and McGuire W.L. Her-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7 (1989) 1120-1128
59. Gusterson B.A., Gelber R.D., Goldhirsch A., et al. Prognostic importance of c-erbb-2 expression in breast cancer. International (ludwig) breast cancer study group. J Clin Oncol 10 (1992) 1049-1056
60. Kroger N., Milde-Langosch K., Riethdorf S., et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12 (2006) 159-168
61. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the her-2/neu oncogene. Science 235 (1987) 177-182
62. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
63. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 (2003) 406-412
64. Petit T., Wilt M., Velten M., et al. Comparative value of tumour grade, hormonal receptors, ki-67, her-2 and topoisomerase ii alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40 (2004) 205-211
65. Pohl G., Rudas M., Taucher S., et al. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78 (2003) 97-103
66. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker ki-67 in early breast cancer. J Clin Oncol 23 (2005) 7212-7220
67. Schmitt M., Harbeck N., Thomssen C., et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78 (1997) 285-296
68. Solomayer E.F., Diel I.J., Wallwiener D., et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 76 (1997) 812-818
69. Duffy M.J., O'Grady P., Devaney D., O'Siorain L., Fennelly J.J., and Lijnen H.J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas, preliminary report. Cancer 62 (1988) 531-533
70. Janicke F., Schmitt M., and Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17 (1991) 303-312
71. Foekens J.A., Look M.P., Peters H.A., van Putten W.L., Portengen H., and Klijn J.G. Urokinase-type plasminogen activator and its inhibitor pai-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87 (1995) 751-756
72. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer-European group on tumor markers recommendations. Tumour Biol 26 (2005) 281-293
73. Myerowitz R.L., Edwards P.A., and Sartiano G.P. Carcinocythemia (carcinoma cell leukemia) due to metastatic carcinoma of the breast: report of a case. Cancer 40 (1977) 3107-3111
74. Gallivan M.V., and Lokich J.J. Carcinocythemia (carcinoma cell leukemia). Report of two cases with english literature review. Cancer 53 (1984) 1100-1102
75. Braun S., Pantel K., Muller P., et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage i, ii, or iii breast cancer. N Engl J Med 342 (2000) 525-533
76. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 (2004) 781-791
77. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
78. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
79. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
80. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
81. Eifel P., Axelson J.A., Costa J., et al. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93 (2001) 979-989
82. Glas A.M., Floore A., Delahaye L.J., et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7 (2006) 278
83. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
84. Chang J.C., Wooten E.C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
85. Yu K., Ganesan K., Miller L.D., and Tan P. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 12 (2006) 3288-3296
86. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
87. Giltnane J.M., and Rimm D.L. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1 (2004) 104-111
88. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80 (2000) 1943-1949
89. Callagy G., Cattaneo E., Daigo Y., et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12 (2003) 27-34
90. Makretsov N.A., Huntsman D.G., Nielsen T.O., et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10 (2004) 6143-6151
91. Abd El-Rehim D.M., Ball G., Pinder S.E., et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cdna expression analyses. Int J Cancer 116 (2005) 340-350
92. Palacios J., Honrado E., Osorio A., et al. Phenotypic characterization of brca1 and brca2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90 (2005) 5-14
93. Ruiz C., Seibt S., Al Kuraya K., et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118 (2006) 2190-2194
94. Espinosa E., Vara J.A., Redondo A., et al. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 23 (2005) 7278-7285
95. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
96. Anderson N.L., and Anderson N.G. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19 (1998) 1853-1861
97. Figeys D., Gygi S.P., Zhang Y., Watts J., Gu M., and Aebersold R. Electrophoresis combined with novel mass spectrometry techniques: powerful tools for the analysis of proteins and proteomes. Electrophoresis 19 (1998) 1811-1818
98. Wilkins M.R., Sanchez J.C., Gooley A.A., et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13 (1996) 19-50
99. Wilkins M.R., Sanchez J.C., Williams K.L., and Hochstrasser D.F. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 17 (1996) 830-838
100. Goncalves A., Esterni B., Bertucci F., et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 25 (2006) 981-989
101. Jatoi I., Tsimelzon A., Weiss H., Clark G.M., and Hilsenbeck S.G. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89 (2005) 173-178
102. Rosen P.P., Groshen S., and Kinne D.W. Prognosis in t2n0m0 stage i breast carcinoma: a 20-year follow-up study. J Clin Oncol 9 (1991) 1650-1661
103. Birgersdotter A., Sandberg R., and Ernberg I. Gene expression perturbation in vitro-a growing case for three-dimensional (3D) culture systems. Semin Cancer Biol 15 (2005) 405-412
104. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., and Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 (2002) 1296-1304
105. Rui Z., Jian-Guo J., Yuan-Peng T., Hai P., and Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 3 (2003) 433-439
106. Carter D., Douglass J.F., Cornellison C.D., et al. Purification and characterization of the mammaglobin/lipophilin b complex, a promising diagnostic marker for breast cancer. Biochemistry 41 (2002) 6714-6722
107. Hudelist G., Singer C.F., Pischinger K.I., et al. Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 6 (2006) 1989-2002
108. Bisca A., D'Ambrosio C., Scaloni A., et al. Proteomic evaluation of core biopsy specimens from breast lesions. Cancer Lett 204 (2004) 79-86
109. Diallo-Danebrock R., Ting E., Gluz O., et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13 (2007) 488-497
110. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
111. Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
112. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med 356 (2007) 294-297
113. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99 (2007) 147-157
114. Ahr A., Karn T., Solbach C., et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359 (2002) 131-132
115. Bosma A.J., Weigelt B., Lambrechts A.C., et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 8 (2002) 1871-1877
116. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
117. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2 (2004) E7
118. Cobleigh M.A., Tabesh B., Bitterman P., et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11 (2005) 8623-8631
119. Esteva F.J., Sahin A.A., Cristofanilli M., et al. Prognostic role of a multigene reverse transcriptase-pcr assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11 (2005) 3315-3319
120. Hicks J., Krasnitz A., Lakshmi B., et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16 (2006) 1465-1479
121. Kreike B., Halfwerk H., Kristel P., et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 12 (2006) 5705-5712
122. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356 (2007) 217-226
123. Nakagawa T., Huang S.K., Martinez S.R., et al. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 66 (2006) 11825-11830
124. Nishidate T., Katagiri T., Lin M.L., et al. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol 25 (2004) 797-819
125. Nuyten D.S., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8 (2006) R62
126. Pawitan Y., Bjohle J., Amler L., et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7 (2005) R953-R964
127. Smid M., Wang Y., Klijn J.G., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 24 (2006) 2261-2267
128. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 (2003) 8418-8423
129. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
130. Folgueira M.A., Carraro D.M., Brentani H., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11 (2005) 7434-7443
131. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
132. Jansen M.P., Foekens J.A., van Staveren I.L., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 (2005) 732-740
133. Nimeus-Malmstrom E., Ritz C., Eden P., et al. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 42 (2006) 2729-2737
134. Sieuwerts A.M., Meijer-van Gelder M.E., Timmermans M., et al. How adam-9 and adam-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11 (2005) 7311-7321
135. Thuerigen O., Schneeweiss A., Toedt G., et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24 (2006) 1839-1845